• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to letter to the editor "The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma".

作者信息

Cheng Yu-Ming, Tzeng I-Shiang, Kao Jia-Horng, Wang Chia-Chi

机构信息

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, Taiwan.

Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.

出版信息

J Formos Med Assoc. 2021 Apr;120(4):1161-1164. doi: 10.1016/j.jfma.2020.12.016. Epub 2020 Dec 24.

DOI:10.1016/j.jfma.2020.12.016
PMID:33358562
Abstract
摘要

相似文献

1
Response to letter to the editor "The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma".对致编辑信《直接抗病毒药物清除丙型肝炎病毒后细胞因子变化对肝细胞癌风险的影响》的回复
J Formos Med Assoc. 2021 Apr;120(4):1161-1164. doi: 10.1016/j.jfma.2020.12.016. Epub 2020 Dec 24.
2
The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
J Formos Med Assoc. 2021 Apr;120(4):1160. doi: 10.1016/j.jfma.2020.11.012. Epub 2020 Dec 5.
3
The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.直接抗病毒药物清除丙型肝炎病毒后细胞因子变化对肝细胞癌风险的影响。
J Formos Med Assoc. 2021 Mar;120(3):965-973. doi: 10.1016/j.jfma.2020.10.015. Epub 2020 Oct 29.
4
Surveillance for hepatocellular carcinoma after hepatitis C virus eradication.
Minerva Med. 2022 Jun;113(3):569-570. doi: 10.23736/S0026-4806.20.06496-4. Epub 2020 Mar 12.
5
Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'.回复：“日本代偿期晚期慢性肝病患者丙型肝炎病毒根除后肝细胞癌的风险分层”
J Hepatol. 2022 Aug;77(2):571-572. doi: 10.1016/j.jhep.2022.04.031. Epub 2022 May 5.
6
Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma.丙型肝炎病毒1b型、肝硬化和肝细胞癌。
Hepatology. 1997 Mar;25(3):772-4. doi: 10.1002/hep.510250347.
7
No differences in the risk of hepatocellular carcinoma from using direct-acting antiviral agents or interferon in patients with chronic hepatitis C: A meta-analysis.
Clin Res Hepatol Gastroenterol. 2022 Dec;46(10):102001. doi: 10.1016/j.clinre.2022.102001. Epub 2022 Aug 12.
8
Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
J Hepatol. 2020 Aug;73(2):469-470. doi: 10.1016/j.jhep.2020.03.035. Epub 2020 Jun 1.
9
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.丙型肝炎治疗革命对肝细胞癌的影响。
Ann Oncol. 2016 Aug;27(8):1467-74. doi: 10.1093/annonc/mdw219. Epub 2016 May 25.
10
Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases.
Rev Gastroenterol Mex (Engl Ed). 2021 Apr-Jun;86(2):197-199. doi: 10.1016/j.rgmx.2020.04.008. Epub 2020 Nov 11.

引用本文的文献

1
Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?老年患者超治疗性利奈唑胺谷浓度：是否需要采取行动？
Clin Pharmacokinet. 2021 May;60(5):603-609. doi: 10.1007/s40262-020-00964-1. Epub 2020 Nov 12.